/주식/IGMS
IGMS

IGMS

USD

IGM Biosciences Inc. Common Stock

$1.218-0.032 (-2.544%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$1.250

고가

$1.270

저가

$1.215

거래량

0.11M

기업 기본 정보

시가총액

73.2M

산업

생명공학

국가

United States

거래 통계

평균 거래량

0.18M

거래소

NMS

통화

USD

52주 범위

저가 $0.92현재가 $1.218고가 $22.5

AI 분석 리포트

마지막 업데이트: 2025년 5월 23일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

IGMS: IGM Biosciences Inc. Common Stock – A Look at Recent Trends and What's Next

Stock Symbol: IGMS Generate Date: 2025-05-23 15:19:05

Let's break down what's been happening with IGM Biosciences and what the numbers might be telling us.

The Latest Buzz (News Sentiment)

Right now, we don't have specific news headlines to go on, so the sentiment from recent news is a bit of a blank slate. This means we're relying heavily on the price action and technical indicators to get a feel for what's driving the stock. Sometimes, no news is... well, just no news, and other factors take the wheel.

What the Stock Price Has Been Doing (Price Action)

Looking at the past few months, IGMS has seen its share of ups and downs. Back in late February, it was hovering around $1.30-$1.40. Then, through March, we saw a gradual drift lower, dipping below $1.20 by late March and early April. It even touched a 52-week low of $0.92 in early April.

However, things picked up mid-April, with the stock climbing back towards the $1.30-$1.40 range. More recently, from early May, there's been another slight pullback, settling around the $1.15-$1.25 mark. Today, May 23rd, the stock is trading around $1.22. The trading volume today, at 33,439 shares, is quite a bit lower than its average, which sits around 173,942. This lower volume on the current day's price action might suggest less conviction behind the move.

The AI's analysis points to the current price being very close to a support level at $1.19. This is an interesting point to note.

Putting It All Together: Outlook & Strategy Ideas

Given the lack of specific news, we're leaning on the technical signals and the AI's insights. The overall picture here suggests a potential buying opportunity for those looking at a short-term trade.

Why does it look that way?

  • Technical Strength: The AI highlights several bullish technical indicators. The DMI (Directional Movement Index) shows a positive trend, and the MACD (Moving Average Convergence Divergence) has a "golden cross," which is often seen as a bullish signal.
  • Volume Spike (Earlier): While today's volume is low, the AI notes a recent surge in trading volume (8.3x average) indicating strong buying pressure. This suggests some significant interest has recently entered the stock.
  • Support Level: The current price being near the $1.19 support level is key. This could act as a floor, making it a potentially attractive entry point.
  • Value Potential: The P/E ratio, while negative, is better than the industry average, which the AI flags as a sign of value.

On the flip side, there are some things to be aware of:

  • Fundamental Weaknesses: The company's revenue growth is low, and its Return on Equity (ROE) is quite poor. Also, the debt-to-equity ratio is very high, which is a significant concern. These fundamental issues mean this isn't a long-term "buy and hold" candidate based on these metrics.
  • Risk Factors: The AI points out high industry-relative debt, small market capitalization, and low trading volume as risk factors. These are important to keep in mind.

So, what's the apparent near-term leaning? It seems to favor potential buyers, especially for those interested in short-term trading.

  • Potential Entry Consideration: If you're considering a move, the area around $1.19 to $1.20 looks like a potential entry point. This aligns with the identified support level and the AI's suggested entry range.
  • Potential Exit/Stop-Loss Consideration: To manage risk, a stop-loss around $1.08 would make sense. This is below recent lows and provides a clear point to exit if the stock moves against expectations. For taking profits, the AI suggests a take-profit level of $1.23. This is a short-term target, reflecting the "short-term trading" investment horizon.

Company Context

IGM Biosciences is a biotechnology company focused on developing antibodies for cancer and autoimmune diseases. It's a relatively small company with 54 employees and a market cap of about $73 million. In the biotech world, news about clinical trials, drug approvals, or research breakthroughs can cause huge swings. Without specific news, we're left to interpret the price action and technicals, but always remember that biotech stocks can be quite volatile. The 52-week high of $22.5 compared to the current price shows just how much this stock can move.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks carries inherent risks, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial professional before making any investment decisions.

관련 뉴스

Analyst Upgrades

Truist Securities Maintains Hold on IGM Biosciences, Lowers Price Target to $1

Truist Securities analyst Asthika Goonewardene maintains IGM Biosciences with a Hold and lowers the price target from $2 to $1.

더 보기
Truist Securities Maintains Hold on IGM Biosciences, Lowers Price Target to $1

AI 예측Beta

AI 추천

약세

업데이트 시간: 2025년 6월 12일 오후 03:57

약세중립강세

57.8% 신뢰도

리스크 & 트레이딩

리스크 수준4/5
고위험
적합 대상
가치
트레이딩 가이드

진입점

$1.36

익절

$1.39

손절

$1.23

핵심 요소

DMI는 약세 추세(ADX:17.3, +DI:8.4, -DI:13.2)를 보여 주의를 요합니다.
현재 가격이 지지선($1.37)에 매우 근접하여 강력한 매수 기회를 시사합니다.
거래량은 평균(3,412)의 8.1배로 극도로 강력한 매수 압력을 나타냅니다.
MACD -0.0029이(가) 신호선 -0.0008 아래에 있어 약세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기